Literature DB >> 9439081

Positron emission tomography studies in headache.

H C Diener1.   

Abstract

Positron emission tomography (PET) allows the quantitative measurement of regional cerebral flow (rCBF) in humans in quantitative terms. Gross changes in rCBF are due to variation in vessel diameter. Changes of rCBF also reflect synaptic activity (inhibition and excitation). Therefore, PET was used to monitor changes in blood flow during the aura and headache phase of a migraine attack and to investigate focal areas of increased or decreased blood flow, e.g., in the brain stem and midbrain. Hemispheric rCBF was unchanged in spontaneous migraine attacks without aura. This was true for the headache side as well as for the nonheadache side. Sumatriptan had no effects on cerebral blood flow. Regional cerebral blood flow was increased in midline brain stem structures during the headache phase, but also when the headache had been treated with sumatriptan. This persisting increased activity might reflect activity of a presumed migraine center in the brain stem. These changes are specific for migraine attacks and are not seen during attacks of cluster headache. Positron emission tomography measurements in the early phase of a migraine attack in a single subject showed flow reductions in the occipital cortex spreading forwards; an observation which would be compatible with the existence of spreading depression in humans. Our attempts to study the aura phase with PET have, to date, been unsuccessful.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9439081     DOI: 10.1046/j.1526-4610.1997.3710622.x

Source DB:  PubMed          Journal:  Headache        ISSN: 0017-8748            Impact factor:   5.887


  11 in total

Review 1.  Where does a migraine attack originate? In the brainstem.

Authors:  J Tajti; D Szok; Á Párdutz; B Tuka; A Csáti; A Kuris; J Toldi; L Vécsei
Journal:  J Neural Transm (Vienna)       Date:  2012-03-18       Impact factor: 3.575

2.  Should magnesium be given to every migraineur? No.

Authors:  Arpad Pardutz; Laszlo Vecsei
Journal:  J Neural Transm (Vienna)       Date:  2012-03-18       Impact factor: 3.575

Review 3.  Kynurenines and headache.

Authors:  Arpád Párdutz; Annamária Fejes; Zsuzsanna Bohár; Lilla Tar; József Toldi; László Vécsei
Journal:  J Neural Transm (Vienna)       Date:  2011-06-04       Impact factor: 3.575

4.  Effects of a selective 5-HT(1B/1D) receptor agonist on spinal and trigeminal reflexes in the anaesthetized rabbit.

Authors:  S Jenkins; B Richardson; R W Clarke
Journal:  Br J Pharmacol       Date:  2000-11       Impact factor: 8.739

5.  Possible sites of action of the new calcitonin gene-related peptide receptor antagonists.

Authors:  Sajedeh Eftekhari; Lars Edvinsson
Journal:  Ther Adv Neurol Disord       Date:  2010-11       Impact factor: 6.570

Review 6.  Migraine is a neuronal disease.

Authors:  J Tajti; A Párdutz; E Vámos; B Tuka; A Kuris; Zs Bohár; A Fejes; J Toldi; L Vécsei
Journal:  J Neural Transm (Vienna)       Date:  2010-12-15       Impact factor: 3.575

7.  Kynurenine metabolites and migraine: experimental studies and therapeutic perspectives.

Authors:  Annamária Fejes; Arpád Párdutz; József Toldi; László Vécsei
Journal:  Curr Neuropharmacol       Date:  2011-06       Impact factor: 7.363

8.  Calcitonin gene-related peptide (CGRP) and its receptor components in human and rat spinal trigeminal nucleus and spinal cord at C1-level.

Authors:  Sajedeh Eftekhari; Lars Edvinsson
Journal:  BMC Neurosci       Date:  2011-11-10       Impact factor: 3.288

9.  Abnormal brain functional connectivity of the hypothalamus in cluster headaches.

Authors:  Enchao Qiu; Yan Wang; Lin Ma; Lixia Tian; Ruozhuo Liu; Zhao Dong; Xian Xu; Zhitong Zou; Shengyuan Yu
Journal:  PLoS One       Date:  2013-02-27       Impact factor: 3.240

Review 10.  Cortical spreading depression as a target for anti-migraine agents.

Authors:  Cinzia Costa; Alessandro Tozzi; Innocenzo Rainero; Letizia Maria Cupini; Paolo Calabresi; Cenk Ayata; Paola Sarchielli
Journal:  J Headache Pain       Date:  2013-07-23       Impact factor: 7.277

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.